Italia markets closed

Brickell Biotech, Inc. (BBI)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,3600+0,0900 (+2,75%)
Alla chiusura: 04:00PM EDT
3,4100 +0,05 (+1,49%)
Dopo ore: 06:24PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,2700
Aperto3,3400
Denaro3,2900 x 3200
Lettera3,4200 x 900
Min-Max giorno3,2100 - 3,4200
Intervallo di 52 settimane2,8800 - 37,3500
Volume92.611
Media Volume270.884
Capitalizzazione8,916M
Beta (5 anni mensile)0,08
Rapporto PE (ttm)N/D
EPS (ttm)-0,4200
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A48,75
  • GlobeNewswire

    Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin

  • GlobeNewswire

    Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

    BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m.

  • GlobeNewswire

    Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

    BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement f